Ioannis Mantzaris
Overview
Explore the profile of Ioannis Mantzaris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mantzaris I, Goldfinger M, Uriel M, Shastri A, Shah N, Gritsman K, et al.
Blood
. 2025 Feb;
PMID: 39919267
Venetoclax combined with intensive chemotherapy shows promise for untreated acute myeloid leukemia (AML), but its integration with the '7+3' regimen remains underexplored. In a phase 1b study (NCT05342584), we assessed...
2.
Cooper D, Verceles J, Kheradmand T, Paroder M, Lombardo A, Goldfinger M, et al.
Br J Haematol
. 2025 Feb;
206(3):1004-1006.
PMID: 39915967
No abstract available.
3.
Amaeshi L, Sofianidi A, Shastri A, Goldfinger M, Konopleva M, Verma A, et al.
Biomark Res
. 2025 Jan;
13(1):4.
PMID: 39773519
FMS-like tyrosine kinase 3 (FLT3) genetic variants are commonly seen in high-grade myeloid neoplasms and are typically gain-of-function mutations associated with a proliferative disease phenotype. Inactivating FLT3 variants have been...
4.
Kamel J, Yan J, Rockwell B, Goldfinger M, Feldman E, Konopleva M, et al.
Leuk Lymphoma
. 2024 Oct;
66(2):329-332.
PMID: 39432864
No abstract available.
5.
Davis T, Fedorov K, Gregos P, Shapiro L, Shastri A, Gritsman K, et al.
J Oncol Res Ther
. 2024 Oct;
8(4).
PMID: 39371330
Introduction: Immune-related adverse events (irAEs) are a group of autoimmune syndromes that arise following therapy with immune checkpoint inhibitors (ICIs) and are characterized by disinhibition of cell-mediated immunity and decreased...
6.
Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica R, et al.
Blood
. 2024 Sep;
144(22):2360-2363.
PMID: 39316768
A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median overall survival for...
7.
Edema U, Liu J, Ma M, Krishnamurthy K, Choudhuri J, Li X, et al.
Am J Clin Pathol
. 2024 Aug;
163(2):205-214.
PMID: 39212661
Objectives: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive mature T-cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1). Its most common immunophenotype is CD4+/CD7-/CD25+, although unusual immunophenotypes can...
8.
Chakraborty S, Morganti C, Pena B, Zhang H, Verma D, Zaldana K, et al.
bioRxiv
. 2024 Aug;
PMID: 39211137
Statement Of Purpose: Five-year survival from AML is dismal at 30%. Our prior research demonstrated STAT3 over-expression in AML HSPC's to be associated with inferior survival. We now explore STAT3...
9.
Issa G, Aldoss I, Thirman M, DiPersio J, Arellano M, Blachly J, et al.
J Clin Oncol
. 2024 Aug;
43(1):75-84.
PMID: 39121437
Purpose: Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated patients with -rearranged...
10.
Yan J, Hammami M, Wei J, Shah N, Goldfinger M, Mantzaris I, et al.
Ann Hematol
. 2024 Jul;
103(9):3543-3551.
PMID: 39046510
The influence of demographic characteristics and social determinants on cancer outcomes is widely recognized in various malignancies but remains understudied in myelofibrosis (MF). This study aims to investigate social and...